BMP-7 (Osteogenic Protein-1)
Overview
BMP-7, also known as osteogenic protein-1 (OP-1), is a member of the bone morphogenetic protein family with a mature homodimeric structure of approximately 139 amino acids per monomer. Like other BMPs, it signals through serine/threonine kinase receptors to activate SMAD transcription factors, promoting differentiation of mesenchymal cells into osteoblasts and chondrocytes.
Mechanism of Action
The recombinant form is delivered on a bovine collagen matrix to provide localized, sustained release. BMP-7 also exhibits renoprotective effects in preclinical models, though clinical development in nephrology has not advanced.
Research Summary & Key Findings
Recombinant human BMP-7 (OP-1 Putty) received FDA approval under a Humanitarian Device Exemption in 2001 for revision posterolateral lumbar spinal fusion and recalcitrant long bone nonunions where autograft is not feasible. Clinical trials demonstrated comparable efficacy to autograft in promoting bone healing in nonunion fractures. The product was voluntarily withdrawn from the U.S. market in 2014 by the manufacturer due to commercial considerations, though it remains available in select international markets.
Clinical Status
BMP-7 (Osteogenic Protein-1) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Administration Routes
References
Primary literature
- PubMed — "BMP-7"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "BMP-7"
Registered interventional and observational studies, including status and phase.
- PubChem — "BMP-7"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Bone
Teriparatide (Forteo)
FDA ApprovedA recombinant form of the first 34 amino acids of human parathyroid hormone (PTH 1-34). When administered intermittently...
View detailsAbaloparatide (Tymlos)
FDA ApprovedA synthetic 34-amino acid peptide analog of parathyroid hormone-related protein (PTHrP 1-34) that selectively activates ...
View detailsCalcitonin
FDA ApprovedA 32-amino acid peptide hormone naturally produced by parafollicular C-cells of the thyroid gland. Calcitonin inhibits o...
View detailsVosoritide (Voxzogo)
FDA ApprovedA C-type natriuretic peptide (CNP) analog that acts as an agonist at the natriuretic peptide receptor B (NPR-B) on growt...
View detailsStart Your Consultation
Get an AI-proposed BMP-7 (Osteogenic Protein-1) protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply BMP-7 (Osteogenic Protein-1).
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.